Three pharma distributors propose a $10 billion plan to a group of state attorneys general in opioid-abuse settlement.
Amgen built on the momentum at a recent conference on its Q2 earnings call as management highlighted recent positive developments for its KRAS inhibitor drug.
Parabolic moves can be alluring, but if you are long on SLP, consider how far it can fall from here.
The trio to keep an eye on are U.S.-China trade talks, business investment and political rhetoric.
Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
Let's check out the latest charts and indicators.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.